Steris (NYSE:STE) had its target price increased by KeyCorp from $135.00 to $138.00 in a research note published on Wednesday, BenzingaRatingsTable reports. KeyCorp currently has an overweight rating on the medical equipment provider’s stock. KeyCorp also issued estimates for Steris’ Q1 2020 earnings at $1.11 EPS, Q2 2020 earnings at $1.25 EPS, Q3 2020 earnings at $1.39 EPS, Q4 2020 earnings at $1.65 EPS, FY2020 earnings at $5.40 EPS and FY2021 earnings at $5.99 EPS.
STE has been the topic of several other reports. Zacks Investment Research upgraded Steris from a sell rating to a hold rating in a research note on Thursday, March 28th. Stephens reaffirmed a buy rating and issued a $135.00 target price on shares of Steris in a research report on Thursday, February 14th. Finally, JMP Securities reaffirmed a buy rating and issued a $135.00 target price on shares of Steris in a research report on Thursday, February 14th. Five investment analysts have rated the stock with a buy rating, The stock has a consensus rating of Buy and a consensus target price of $145.20.
STE traded down $0.37 during trading hours on Wednesday, hitting $133.35. 419,038 shares of the stock were exchanged, compared to its average volume of 487,863. Steris has a 12 month low of $99.14 and a 12 month high of $135.97. The stock has a market capitalization of $11.31 billion, a PE ratio of 27.27 and a beta of 1.06. The company has a debt-to-equity ratio of 0.37, a current ratio of 2.27 and a quick ratio of 1.99.
The business also recently announced a quarterly dividend, which will be paid on Friday, June 28th. Shareholders of record on Wednesday, June 12th will be given a $0.34 dividend. This represents a $1.36 annualized dividend and a yield of 1.02%. The ex-dividend date of this dividend is Tuesday, June 11th. Steris’s dividend payout ratio is presently 27.81%.
In other Steris news, CEO Walter M. Rosebrough, Jr. sold 50,000 shares of the stock in a transaction on Thursday, March 21st. The stock was sold at an average price of $125.00, for a total value of $6,250,000.00. Following the sale, the chief executive officer now directly owns 98,895 shares of the company’s stock, valued at $12,361,875. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, Director Cynthia L. Feldmann sold 2,037 shares of the stock in a transaction on Wednesday, February 20th. The stock was sold at an average price of $122.51, for a total value of $249,552.87. Following the completion of the sale, the director now directly owns 10,700 shares in the company, valued at $1,310,857. The disclosure for this sale can be found here. Insiders sold 59,255 shares of company stock worth $7,416,275 over the last ninety days. 2.38% of the stock is owned by corporate insiders.
A number of hedge funds and other institutional investors have recently modified their holdings of the business. Nordea Investment Management AB acquired a new position in Steris during the third quarter worth about $4,653,000. Vanguard Group Inc grew its holdings in Steris by 1.8% during the third quarter. Vanguard Group Inc now owns 7,516,051 shares of the medical equipment provider’s stock worth $859,837,000 after acquiring an additional 133,510 shares during the period. State of Alaska Department of Revenue grew its holdings in Steris by 2.0% during the fourth quarter. State of Alaska Department of Revenue now owns 8,892 shares of the medical equipment provider’s stock worth $950,000 after acquiring an additional 172 shares during the period. First Hawaiian Bank grew its holdings in Steris by 144.9% during the fourth quarter. First Hawaiian Bank now owns 2,273 shares of the medical equipment provider’s stock worth $243,000 after acquiring an additional 1,345 shares during the period. Finally, Gateway Investment Advisers LLC acquired a new position in Steris during the fourth quarter worth about $1,197,000. 86.81% of the stock is currently owned by hedge funds and other institutional investors.
STERIS plc provides infection prevention and other procedural products and services worldwide. The company operates in four segments: Healthcare Products, Healthcare Specialty Services, Life Sciences, and Applied Sterilization Technologies. The Healthcare Products segment offers cleaning chemistries and sterility assurance products; accessories for gastrointestinal (GI) procedures, washers, sterilizers, and other pieces of capital equipment for the operations of a sterile processing department; and equipment used in the operating room, including surgical tables, lights, equipment management services, and connectivity solutions.
Read More: Book Value Per Share – BVPS
Receive News & Ratings for Steris Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Steris and related companies with MarketBeat.com's FREE daily email newsletter.